人类胚胎多次玻璃化冷冻复苏与活检的临床结局及子代新生儿随访
回顾性观察2015年3月至2019年12月97个周期,对玻璃化复苏囊胚行滋养层活检后再二次玻璃化。二次玻璃化单次活检组临床妊娠率46%,与同期单次玻璃化单次活检相当;二次玻璃化二次活检组临床妊娠率35.0%,似较低但需进一步研究。已出生13名单胎,新生儿随访未见不良影响。
要点
- 二次玻璃化单次活检囊胚临床妊娠率46%,与单次玻璃化单次活检相当。
- 二次玻璃化二次活检组临床妊娠率35.0%,低于单次活检组44.0%,但差异无统计学意义(P=0.54)。
- 已出生13名单胎,新生儿随访结果令人安心,未见不良影响。
核心结论
- 对玻璃化复苏囊胚行二次玻璃化及单次或二次活检可获得健康活产,二次玻璃化单次活检临床妊娠率与单次玻璃化单次活检相当。
- 二次玻璃化二次活检囊胚的临床妊娠率似较低,需进一步研究。
研究设计与样本
- 回顾性观察研究,纳入2015年3月至2019年12月97个滋养层活检及胚胎植入前遗传学检测(PGT)周期,涉及玻璃化复苏胚胎及二次玻璃化。
- 单次活检组36个复苏周期,二次活检组61个复苏周期(其中Day 3活检4例,Day 5/6活检57例)。
主要发现
- 共复苏91枚卵裂期胚胎和154枚囊胚,分别有34枚(37.4%)和126枚(81.8%)质量合格可行滋养层活检并二次玻璃化。
- 其中92枚首次活检(单次活检),68枚二次活检(二次活检);诊断后可移植囊胚77枚(48.1%),单次活检组44枚,二次活检组33枚。
- 46个复苏周期中复苏51枚囊胚,二次复苏存活49枚(96.0%);随后45个冻融胚胎移植(FET)周期,获27例生化妊娠和18例临床妊娠(每FET周期40.0%:单次活检组44.0%,二次活检组35.0%,P=0.54)。
- 已出生13名单胎(单次活检组8名,二次活检组5名),另有3例妊娠持续中;共26枚胚胎(每组13枚)仍冷冻保存。
关键数值与推荐
- 二次玻璃化单次活检囊胚临床妊娠率46%(2016-2018年同期本中心数据),与单次玻璃化单次活检相当。
- 每FET周期临床妊娠率40.0%(单次活检组44.0% vs 二次活检组35.0%,P=0.54)。
- 二次复苏存活率96.0%(49/51)。
临床怎么用
- 对玻璃化复苏胚胎行PGT包括二次玻璃化步骤可获得健康活产,单次和二次活检均可行。
- 二次玻璃化二次活检囊胚妊娠潜力可能较低,咨询时应告知需进一步研究。
- 已出生子代新生儿随访未见不良影响,可用于咨询再活检和二次玻璃化的安全性。
局限性
- 小样本回顾性队列,二次玻璃化二次活检囊胚的种植潜力需进一步研究。
- 样本量过小,无法比较单次或二次活检后单胎出生体重的标准差评分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does double vitrification and warming of human blastocysts having undergone biopsy once or twice have an impact on the clinical outcome? SUMMARY ANSWER: The clinical pregnancy rate obtained with double vitrification single biopsy blastocysts was comparable to that obtained with single vitrification single biopsy blastocysts in our center in the same time period (46%; 2016-2018), whereas that obtained with double-vitrified double-biopsied blastocysts seemed lower and will need further study. WHAT IS KNOWN ALREADY: Genetic testing on cryopreserved unbiopsied embryos involves two cryopreservation procedures. Retesting of failed/inconclusive-diagnosed blastocysts inevitably involves a second round of biopsy and a second round of vitrification as well. To what extent this practice impacts on the developmental potential of blastocysts has been studied to a limited extent so far and holds controversy. Additionally, the obstetrical/perinatal outcome after the transfer of double-vitrified/single or double-biopsied blastocysts is poorly documented. STUDY DESIGN, SIZE, DURATION: This retrospective observational study included 97 cycles of trophectoderm biopsy and preimplantation genetic testing (PGT) on vitrified-warmed embryos followed by a second round of vitrification between March 2015 and December 2019. PARTICIPANTS/MATERIALS, SETTING, METHODS: In 36 warming cycles, no biopsy was performed on the embryos before the first vitrification (single biopsy group). In 61 warming cycles, the embryos had been biopsied on Day 3 (n = 4) or on Day 5/6 (n = 57) before the first vitrification (double biopsy group). A second biopsy was mostly indicated in cycles of failed or inconclusive diagnosis at the first biopsy. Two cycles involved a more specific mutation test for X-linked diseases on male embryos and one cycle involved testing for a second monogenic indication supplementary to a previously tested reciprocal translocation. Post-warming suitability for biopsy, availability of genetically transferable embryos and clinical outcome of subsequent frozen-thawed embryo transfer (FET) cycles were reported. Neonatal follow-up of the children was included. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 91 cleavage-stage embryos and 154 blastocysts were warmed, of which 34 (37.4%) and 126 (81.8%), respectively, were of sufficient quality to undergo trophectoderm biopsy and were subsequently vitrified for a second time. Out of these, 92 underwent biopsy for the first time (single biopsy), whereas 68 underwent a second biopsy (double biopsy). After diagnosis, 77 blastocysts (48.1%) were revealed to be genetically transferable (44 in the single biopsy group and 33 in the double biopsy group). In 46 warming cycles, 51 blastocysts were warmed and 49 survived this second warming procedure (96.0%). Subsequently, there were 45 FET cycles resulting in 27 biochemical pregnancies and 18 clinical pregnancies with fetal heartbeat (40.0% per FET cycle: 44.0% in the single biopsy group and 35.0% in the double biopsy group, P = 0.54). Thirteen singletons were born (eight in the single biopsy group and five in the double biopsy group), while three pregnancies were ongoing. A total of 26 embryos (13 in each group) remain vitrified and have the potential to increase the final clinical pregnancy rate. The neonatal follow-up of the children born so far is reassuring. LIMITATIONS, REASONS FOR CAUTION: This is a small retrospective cohort, thus, the implantation potential of double vitrification double biopsy blastocysts, as compared to double vitrification single biopsy blastocysts and standard PGT (single vitrification, single biopsy), certainly needs further investigation. Although one could speculate on birthweight being affected by the number of biopsies performed, the numbers in this study are too small to compare birthweight standard deviation scores in singletons born after single or double biopsy. WIDER IMPLICATIONS OF THE FINDINGS: PGT on vitrified-warmed embryos, including a second vitrification-warming step, results in healthy live birth deliveries, for both single- and double-biopsied embryos. The neonatal follow-up of the 13 children born so far did not indicate any adverse effect. The present study is important in order to provide proper counseling to couples on their chance of a live birth per initial warming cycle planned and concerning the safety issue of rebiopsy and double vitrification. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: N/A.
引用
- De Vos A, Van Landuyt L, De Rycke M, et al. Multiple vitrification-warming and biopsy procedures on human embryos: clinical outcome and neonatal follow-up of children. Hum Reprod. 2020. PMID: 33047114. doi:10.1093/humrep/deaa236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。